The purpose of this study is to obtain safety and tolerability data of the study drug known as LY4065967 and rosuvastatin in healthy Japanese participants. Blood tests will be performed to check how much LY4065967 and rosuvastatin get into the bloodstream and how long it takes the body to eliminate it. This is a 3-part study and will last approximately 2 weeks excluding screening period for each part.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Enrollment
59
Souseikai Fukuoka Mirai Hospital
Fukuoka, Japan
Part A: Number of Participants with Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered to be Related to Study Drug Administration
Part A: A summary of TEAEs and SAEs regardless of causality, will be reported in the Reported Adverse Events module
Time frame: Baseline to 7 Days
Part B: Number of Participants with Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered to be Related to Study Drug Administration
Part B: A summary of TEAEs and SAEs regardless of causality, will be reported in the Reported Adverse Events module
Time frame: Baseline to 12 Days
Part D: PK: Maximum Concentration (Cmax) of Rosuvastatin
Part D: PK: Cmax of Rosuvastatin
Time frame: Predose on Day 1 Through 72 Hours Post-Dose
Part D: PK: Area Under the Concentration Versus Time Curve (AUC) of Rosuvastatin
Part D: PK: AUC of Rosuvastatin
Time frame: Predose on Day 1 Through 72 Hours Post-Dose
Part A : Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY4065967
Part A: PK: Cmax of LY4065967
Time frame: Predose on Day 1 Through 48 Hours Post-Dose
Part B: PK: Cmax of LY4065967
Part B: PK: Cmax of LY4065967
Time frame: Predose on Day 1 Through Day 9
Part A and B: PK: Area Under the Concentration Versus Time Curve (AUC) of LY4065967
Part A and B: PK: AUC of LY4065967
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: Predose on Day 1 Through 48 Hours Post-Dose
Part D: Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY4065967
Part D: PK: Cmax of LY4065967
Time frame: Day 5 Through Day 11
Part D: PK: Area Under the Concentration Versus Time Curve (AUC) of LY4065967
Part D: PK: AUC of LY4065967
Time frame: Day 5 Through Day 11